Skip to main content

Advertisement

SpringerLink
Log in

Treatments of gliosarcoma of the brain: a systematic review and meta-analysis

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Gliosarcoma (GSM) is a rare central nervous system tumor. Clinical management of it is similar to glioblastoma (GBM). However, due to a few comparative studies exist, uncertainty and disagreements remain in the literatures. To assess the available evidence on the value of different treatments and to carry out an up-to-date evaluation to summarize the evidence for the optimal treatment in GSM patients. Free words were used to search for the relevant studies without language limitations in electronic databases including PubMed, Ovid EMBASE, Cochrane Central Register of Controlled Trials from inception to September 15, 2019. Pooled hazard ratio (HR) with 95% confidence interval (CI) were calculated using a random-effects model. The main endpoint was all-cause mortality. Overall, 10 studies published between 2008 and 2018 including 803 patients were selected for the meta-analysis. Temozolomide (TMZ)-dominated chemotherapy was associated with a reduced risk of overall survival (OS), with HR 0.49 (95% CI 0.37–0.66). The pooled HR of OS was 0.40 (95% CI 0.29–0.56) between radiotherapy and without radiotherapy. The pooled HR (0.52, 95% CI 0.32–0.85) indicated gross total resection (GTR) had a positive impact on OS in GSM. In patients with GSM, survival benefits as currently performed are associated with TMZ-dominated chemotherapy and high-dose radiotherapy. Our systematic review and meta-analysis also demonstrate GTR is associated with a reduction in all-cause mortality in patients with primary GSM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ra M, Feigin I, Ransohoff J 3rd (1976) Clinical and pathological study of 24 cases of gliosarcoma. J Neurosurg 45(4):398. https://doi.org/10.3171/jns.1976.45.4.0398

    Article  Google Scholar 

  2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol Commun 114(2):13

    Google Scholar 

  3. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O’Fallon JR, Farr G Jr (1998) Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. J Neurosurg 89(3):425. https://doi.org/10.3171/jns.1998.89.3.0425

    Article  CAS  PubMed  Google Scholar 

  4. Feigin IH, Gross SW (1955) Sarcoma arising in glioblastoma of the brain. Am J Pathol 31(4):21

    Google Scholar 

  5. Beaumont TL, Kupsky WJ, Barger GR, Sloan AE (2007) Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J Neurooncol 83(1):39–46. https://doi.org/10.1007/s11060-006-9295-x

    Article  PubMed  Google Scholar 

  6. Frandsen S, Broholm H, Larsen VA, Grunnet K, Moller S, Poulsen HS, Michaelsen SR (2019) Clinical characteristics of gliosarcoma and outcomes from standardized treatment relative to conventional glioblastoma. Front Oncol 9:1425. https://doi.org/10.3389/fonc.2019.01425

    Article  PubMed  PubMed Central  Google Scholar 

  7. Meis JM, Martz KL, Nelson JS (1991) Mixed glioblastoma multiforme and sarcoma. A clinicopathologic study of 26 radiation therapy oncology group cases. Cancer 67(9):8. https://doi.org/10.1002/1097-0142(19910501)67:9

    Article  Google Scholar 

  8. Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D, Henriksson R, Balana C, Chinot O, Ram Z, Reifenberger G, Soffietti R, Wick W (2014) EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15(9):e395–e403. https://doi.org/10.1016/S1470-2045(14)70011-7

    Article  PubMed  Google Scholar 

  9. Yi X, Cao H, Tang H, Gong G, Hu Z, Liao W, Sun L, Chen BT, Li X (2019) Gliosarcoma: a clinical and radiological analysis of 48 cases. Eur Radiol 29(1):429–438. https://doi.org/10.1007/s00330-018-5398-y

    Article  PubMed  Google Scholar 

  10. Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018) Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg 128(4):1133–1138. https://doi.org/10.3171/2016.12.jns162291

    Article  PubMed  Google Scholar 

  11. Barker FG 2nd, Md P, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK, Wara WM, Wilson CB (1996) Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84(3):442–448. https://doi.org/10.3171/jns.1996.84.3.0442

    Article  PubMed  Google Scholar 

  12. Cai J, Wu Y, Mirua T, Pierce JL, Lucero MT, Albertine KH, Spangrude GJ, Rao MS (2002) Properties of a fetal multipotent neural stem cell (NEP cell). Dev Biol 251(2):22. https://doi.org/10.1006/dbio.2002.0828

    Article  CAS  Google Scholar 

  13. Jaros E, Rh P, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66(0007–0920):13. https://doi.org/10.1038/bjc.1992.273

    Article  Google Scholar 

  14. Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(1533–4406 (Electronic)):987–996. https://doi.org/10.1056/NEJMoa043330

    Article  CAS  PubMed  Google Scholar 

  15. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A (2017) NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Cancer Netw 15(11):1331–1345. https://doi.org/10.6004/jnccn.2017.0166

    Article  Google Scholar 

  16. Walker G, Mr G, Prabhu SS, Brown PD, McAleer MF (2013) Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice. J Neurooncol 112(1):7

    Article  Google Scholar 

  17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. BioMed Central. https://doi.org/10.1186/1745-6215-8-16

    Article  Google Scholar 

  19. Margulis AV, Pladevall M, Riera-Guardia N, Varas-Lorenzo C, Hazell L, Berkman ND, Viswanathan M, Perez-Gutthann S (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 6:359–368. https://doi.org/10.2147/clep.s66677

    Article  PubMed  PubMed Central  Google Scholar 

  20. Smith DR, Wu CC, Saadatmand HJ, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, Wang SH, Canoll P, McKhann GM 2nd, Wang TJC (2018) Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. J Neurooncol 137(2):303–311. https://doi.org/10.1007/s11060-017-2718-z

    Article  CAS  PubMed  Google Scholar 

  21. Shin JY, Yoon JK, Diaz AZ (2017) Gliosarcoma in septuagenarians and octogenarians: what is the impact of adjuvant chemoradiation? J Clin Neurosci 45:77–82. https://doi.org/10.1016/j.jocn.2017.07.002

    Article  PubMed  Google Scholar 

  22. Jain A, Correia J, Schweder P, McMahon A, Merola J, Aspoas R (2017) Analysis of outcomes of multidisciplinary management of gliosarcoma: a single-center study, 2000–2013. World Neurosurg 106:30–36. https://doi.org/10.1016/j.wneu.2017.06.073

    Article  PubMed  Google Scholar 

  23. Castelli J, Feuvret L, Haoming QC, Biau J, Jouglar E, Berger A, Truc G, Gutierrez FL, Morandi X, Le Reste PJ, Thillays F, Loussouarn D, Nouhaud E, Crehange G, Antoni D, Vauleon E, de Crevoisier R, Noel G (2016) Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. J Neurooncol 129(1):85–92. https://doi.org/10.1007/s11060-016-2142-9

    Article  CAS  PubMed  Google Scholar 

  24. Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J (2016) Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J Neurooncol 128(2):341–348. https://doi.org/10.1007/s11060-016-2117-x

    Article  CAS  PubMed  Google Scholar 

  25. Rath GK, Sharma DN, Mallick S, Gandhi AK, Joshi NP, Haresh KP, Gupta S, Julka PK (2015) Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. Indian J Cancer 52(4):599–603. https://doi.org/10.4103/0019-509X.178407

    Article  CAS  PubMed  Google Scholar 

  26. Lee D, Kang SY, Suh YL, Jeong JY, Lee JI, Nam DH (2012) Clinicopathologic and genomic features of gliosarcomas. J Neurooncol 107(3):643–650. https://doi.org/10.1007/s11060-011-0790-3

    Article  PubMed  Google Scholar 

  27. Kang SH, Park KJ, Kim CY, Yu MO, Park CK, Park SH, Chung YG (2011) O6-methylguanine DNA methyltransferase status determined by promoter methylation and immunohistochemistry in gliosarcoma and their clinical implications. J Neurooncol 101(3):477–486. https://doi.org/10.1007/s11060-010-0267-9

    Article  CAS  PubMed  Google Scholar 

  28. Han SJ, Yang I, Ahn BJ, Otero JJ, Tihan T, McDermott MW, Berger MS, Prados MD, Parsa AT (2010) Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer 116(5):1358–1366. https://doi.org/10.1002/cncr.24857

    Article  PubMed  Google Scholar 

  29. Kozak KR, Mahadevan A, Moody JS (2009) Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol 11(2):9. https://doi.org/10.1215/15228517-2008-076)

    Article  Google Scholar 

  30. Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M (2016) Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol 2(11):1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373

    Article  PubMed  PubMed Central  Google Scholar 

  31. Loureiro LV, Victor Eda S, Callegaro-Filho D, Koch Lde O, Pontes Lde B, Weltman E, Rother ET, Malheiros SM (2016) Minimizing the uncertainties regarding the effects of delaying radiotherapy for glioblastoma: a systematic review and meta-analysis. Radiother Oncol 118(1):1–8. https://doi.org/10.1016/j.radonc.2015.11.021

    Article  PubMed  Google Scholar 

  32. Sun H, Du S, Liao G, Xie X, Ren C, Yuan YW (2015) Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis. Medicine (Baltimore) 94(20):e827. https://doi.org/10.1097/md.0000000000000827

    Article  CAS  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, West China Hospital, Sichuan University, No. 37, St. Guoxuexiang, Chengdu, 610041, Sichuan, People’s Republic of China

    Xing Wang & Chao You

  2. Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People’s Republic of China

    Jiao Jiang

  3. Department of Rehabilitation, Huashan Hospital, Fudan University, Shanghai, 200040, People’s Republic of China

    Meixi Liu

  4. West China Brain Research Centre, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, People’s Republic of China

    Chao You

Authors
  1. Xing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meixi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chao You
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CY was the guarantor of the review. Concept and design: XW, CY; Acquisition, analysis, or interpretation of data: XW, JJ, ML; Drafting of the manuscript: XW, JJ, ML; Statistical analysis: XW, JJ, ML; Supervision: XW, CY.

Corresponding author

Correspondence to Chao You.

Ethics declarations

Conflict of interest

The author declares that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors, thus ethical approval is not required.

Informed consent

For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 3302 KB)

Supplementary file2 (DOC 67 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, X., Jiang, J., Liu, M. et al. Treatments of gliosarcoma of the brain: a systematic review and meta-analysis. Acta Neurol Belg 121, 1789–1797 (2021). https://doi.org/10.1007/s13760-020-01533-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-020-01533-w

Keywords

Search

Navigation